PL2990400T3 - Związek kwasu dikarboksylowego - Google Patents

Związek kwasu dikarboksylowego

Info

Publication number
PL2990400T3
PL2990400T3 PL14787530T PL14787530T PL2990400T3 PL 2990400 T3 PL2990400 T3 PL 2990400T3 PL 14787530 T PL14787530 T PL 14787530T PL 14787530 T PL14787530 T PL 14787530T PL 2990400 T3 PL2990400 T3 PL 2990400T3
Authority
PL
Poland
Prior art keywords
dicarboxylic acid
acid compound
compound
dicarboxylic
acid
Prior art date
Application number
PL14787530T
Other languages
English (en)
Inventor
Yoshikazu Uto
Mikio Kato
Hidenori Takahashi
Yasuyuki Ogawa
Osamu Iwamoto
Hiroko Kono
Kazumasa Aoki
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of PL2990400T3 publication Critical patent/PL2990400T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL14787530T 2013-04-24 2014-04-23 Związek kwasu dikarboksylowego PL2990400T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013091090 2013-04-24
PCT/JP2014/061390 WO2014175317A1 (ja) 2013-04-24 2014-04-23 ジカルボン酸化合物
EP14787530.6A EP2990400B1 (en) 2013-04-24 2014-04-23 Dicarboxylic acid compound

Publications (1)

Publication Number Publication Date
PL2990400T3 true PL2990400T3 (pl) 2017-10-31

Family

ID=51791887

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14787530T PL2990400T3 (pl) 2013-04-24 2014-04-23 Związek kwasu dikarboksylowego

Country Status (28)

Country Link
US (2) US9617232B2 (pl)
EP (1) EP2990400B1 (pl)
JP (1) JP5774253B2 (pl)
KR (1) KR102168259B1 (pl)
CN (3) CN107337621A (pl)
AU (1) AU2014258419B2 (pl)
BR (1) BR112015026840A2 (pl)
CA (1) CA2909400C (pl)
CY (1) CY1119296T1 (pl)
DK (1) DK2990400T3 (pl)
ES (1) ES2640802T3 (pl)
HR (1) HRP20171273T1 (pl)
HU (1) HUE034554T2 (pl)
IL (1) IL242195B (pl)
LT (1) LT2990400T (pl)
MX (1) MX2015014921A (pl)
MY (1) MY170262A (pl)
NZ (1) NZ712660A (pl)
PH (1) PH12015502429B1 (pl)
PL (1) PL2990400T3 (pl)
PT (1) PT2990400T (pl)
RS (1) RS56243B1 (pl)
RU (1) RU2662817C2 (pl)
SG (1) SG11201508542SA (pl)
SI (1) SI2990400T1 (pl)
SM (1) SMT201700438T1 (pl)
TW (1) TWI594975B (pl)
WO (1) WO2014175317A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI594975B (zh) * 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
CN107074793B (zh) * 2014-09-26 2019-08-23 第一三共株式会社 二羧酸化合物的盐
TW201700458A (zh) * 2015-04-24 2017-01-01 第一三共股份有限公司 二羧酸化合物之製法
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
CA3049010A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
CA3094527A1 (en) * 2018-03-23 2019-09-26 Yumanity Therapeutics, Inc. Compounds and uses thereof
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
WO2023219127A1 (ja) * 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ231939A (en) 1988-12-28 1991-07-26 Takeda Chemical Industries Ltd Benzothiopyran derivatives and medicaments
DD280329A1 (de) * 1989-03-09 1990-07-04 Bitterfeld Chemie Dispersionsfarbstoffpraeparate zum faerben und bedrucken von polyestermaterialien i
TW575563B (en) * 1997-08-19 2004-02-11 American Cyanamid Co Process for the preparation of pyridyl carboxylic amides and esters
JPWO2003048134A1 (ja) * 2001-12-05 2005-04-14 日本たばこ産業株式会社 トリアゾール化合物及びその医薬用途
AU2003265382A1 (en) * 2002-08-23 2004-03-11 Pharmacia & Upjohn Company Llc Antibacterial benzoic acid derivatives
WO2004085382A1 (ja) * 2003-03-27 2004-10-07 Kirin Beer Kabushiki Kaisha 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
FR2872159B1 (fr) 2004-06-28 2007-10-05 Merck Sante Soc Par Actions Si Nouveaux derives acides carboxyliques phenyliques et leur utilisation dans le traitement du diabete
CA2727340A1 (en) * 2008-06-25 2009-12-30 Daiichi Sankyo Company, Limited Carboxylic acid compound
CA2929347A1 (en) 2009-05-26 2010-12-02 Milan Bruncko (hetero)aryl substituted sulfonyl-2-(1h-pyrrolo[2,3-b]pyridine-5-oxy)benzamide compounds and their use as apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
DE102009046115A1 (de) 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
AU2011240774B2 (en) 2010-04-12 2014-04-10 Otsuka Pharmaceutical Co., Ltd. Aptamers to beta-NGF and their use in treating beta-NGF mediated diseases and disorders
EP2565190B1 (en) 2010-04-28 2015-06-03 Astellas Pharma Inc. Tetrahydrobenzothiophene compound
EP2591354B1 (en) * 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590656B1 (en) * 2010-07-07 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
CN103906741B (zh) * 2011-10-27 2016-01-20 安斯泰来制药株式会社 氨烷基取代的n-噻吩基苯甲酰胺衍生物
WO2013082756A1 (en) * 2011-12-06 2013-06-13 Leo Pharma A/S Phosphate transport inhibitors ii
WO2013082751A1 (en) * 2011-12-06 2013-06-13 Leo Pharma A/S Phosphate transport inhibitors i
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
TWI594975B (zh) * 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
CN107074793B (zh) * 2014-09-26 2019-08-23 第一三共株式会社 二羧酸化合物的盐

Also Published As

Publication number Publication date
SG11201508542SA (en) 2015-11-27
NZ712660A (en) 2019-10-25
CN107311895A (zh) 2017-11-03
US9617232B2 (en) 2017-04-11
US9670173B2 (en) 2017-06-06
SI2990400T1 (sl) 2017-08-31
CY1119296T1 (el) 2018-02-14
US20160046568A1 (en) 2016-02-18
CN105121405A (zh) 2015-12-02
CN107337621A (zh) 2017-11-10
SMT201700438T1 (it) 2017-11-15
HRP20171273T1 (hr) 2017-10-20
AU2014258419A2 (en) 2015-11-19
AU2014258419A1 (en) 2015-10-22
US20170015641A1 (en) 2017-01-19
MX2015014921A (es) 2016-06-02
PT2990400T (pt) 2017-09-25
ES2640802T3 (es) 2017-11-06
AU2014258419B2 (en) 2018-08-09
CA2909400A1 (en) 2014-10-30
HUE034554T2 (en) 2018-02-28
PH12015502429A1 (en) 2016-02-22
BR112015026840A2 (pt) 2017-07-25
EP2990400A4 (en) 2016-10-19
WO2014175317A1 (ja) 2014-10-30
TWI594975B (zh) 2017-08-11
MY170262A (en) 2019-07-15
RS56243B1 (sr) 2017-11-30
KR20160002743A (ko) 2016-01-08
CA2909400C (en) 2017-06-27
RU2662817C2 (ru) 2018-07-31
EP2990400B1 (en) 2017-06-21
IL242195B (en) 2019-08-29
RU2015150120A (ru) 2017-05-29
EP2990400A1 (en) 2016-03-02
JP5774253B2 (ja) 2015-09-09
KR102168259B1 (ko) 2020-10-21
LT2990400T (lt) 2017-09-11
TW201500338A (zh) 2015-01-01
PH12015502429B1 (en) 2018-10-12
JPWO2014175317A1 (ja) 2017-02-23
DK2990400T3 (da) 2017-10-09
HK1222385A1 (en) 2017-06-30

Similar Documents

Publication Publication Date Title
IL249517A0 (en) A compound that inhibits trk
GB201311891D0 (en) Novel compound
SG11201600759XA (en) Novel quinoline-substituted compound
GB201302368D0 (en) Compound
ZA201507044B (en) Pyridinylpyrazoloquinoline compound
SG11201508542SA (en) Dicarboxylic acid compound
ME03398B (me) Spojevi dimetilbenzojeve kiseline
GB201318222D0 (en) Novel compounds
ZA201506745B (en) Guanidinobenzoic acid ester compound
GB201303158D0 (en) Ritalinic Acid Immunoassay
GB201408643D0 (en) Compound
GB201307331D0 (en) Compound
GB201322438D0 (en) Compound
GB201315772D0 (en) Compound
GB201305634D0 (en) Compound
GB201304250D0 (en) Compound
GB201301585D0 (en) Compound
TH1401007860A (th) สารประกอบไดเมธิล-เบนโซอิค แอซิด